Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, and other medical equipment. In-home sleep testing provides in home sleep apnea testing services. Healthcare staffing provides healthcare staffing and recruitment services. The Company provides home medical equipment services through its interest in East Alabama HomeMed, LLC (HomeMed).


NDAQ:VMD - Post by User

Comment by Joe455on Feb 28, 2022 2:19pm
113 Views
Post# 34468526

RE:Vent Patients

RE:Vent Patients
donmayne wrote: VMD's core business is with vent patients.  Up to June 2019, their average growth was 8.8%.  Since then, their average growth was 1.6%.  Their incentive compensation awards are unjustified in the face of the recent under-performance.  The only consolation for the retail investor is that management stock holdings were also negatively affected so they cannot walk away now.  
 
Quarter end Vent Patients Quarterly change % change
2021-09-30 8,200 97 1.2%
2021-06-30 8,103 370 4.8%
2021-03-31 7,733 -159 -2.0%
2020-12-31 7,892 104 1.3%
2020-09-30 7,788 83 1.1%
2020-06-30 7,705 -260 -3.3%
2020-03-31 7,965 206 2.7%
2019-12-31 7,759 338 4.6%
2019-09-30 7,421 291 4.1%
2019-06-30 7130 737 11.5%
2019-03-31 6,393 488 8.3%
2018-12-31 5,905 461 8.5%
2018-09-30 5,444 366 7.2%
2018-06-30 5,078 393 8.4%
2018-03-31 4,685    

2021-Q4 was a period post-Delta. Omicron took hold in mid-December when it would have affected patient uploads. The results in Q4 should provide a glimpse of growth in vent patients post pandemic.  Guidance from the company for 2022-Q1 will be quite accurate because they will know the first two months.  But it will be conservative growth and not meaningful because it will reflect an Omicron impact for the first six weeks of 2022. It is because of Omicron that Investors will be looking for revenue and profit guidance farther down the road than Q1 2022.
 



Thanks for the good info.
<< Previous
Bullboard Posts
Next >>